Skip Navigation



Human Molecular Genetics Advance Access published online on January 2, 2007
Human Molecular Genetics, doi:10.1093/hmg/ddl472
This Article
Right arrow Advance Access manuscript (PDF) Freely available
Right arrow Supplementary Data
Right arrowOA All Versions of this Article:
16/3/327    most recent
ddl472v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Esapa, C. T.
Right arrow Articles by Blake, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Esapa, C. T.
Right arrow Articles by Blake, D. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 The Author(s)
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

SGCE missense mutations that cause myoclonus-dystonia syndrome impair {epsilon}-sarcoglycan trafficking to the plasma membrane: modulation by ubiquitination and torsinA

Christopher T. Esapa+, Adrian Waite+, Matthew Locke, Matthew A. Benson, Michaela Krauss1, R. A. Jeffrey McIlhinney2, Roy V. Sillitoe3, Philip W. Beesley1 and Derek J. Blake*

Department of Pharmacology, University of Oxford, Mansfield Road, Oxford, OX1 3QT, UK 1 School of Biological Sciences, Royal Holloway, University of London, Egham, Surrey, TW20 0EX, UK 2 Medical Research Council Anatomical Neuropharmacology Unit, University of Oxford, Mansfield Road, Oxford, OX1 3QT, UK

* Corresponding author: Dr Derek J. Blake, Department of Pharmacology, University of Oxford, Mansfield Road, Oxford, OX1 3QT, UK. Tel.: +44 1865 271860; Fax: +44 1865 271853; e-mail: derek.blake{at}pharm.ox.ac.uk

Received November 13, 2006; Revised December 15, 2006; Accepted December 15, 2006

Myoclonus-dystonia syndrome (MDS) is a genetically heterogeneous disorder characterized by myoclonic jerks often seen in combination with dystonia and psychiatric co-morbidities and epilepsy. Mutations in the gene encoding {epsilon}-sarcoglycan (SGCE) have been found in some patients with MDS. SGCE is a maternally imprinted gene with the disease being inherited in an autosomal dominant pattern with reduced penetrance upon maternal transmission. In the central nervous system, {epsilon}-sarcoglycan is widely expressed in neurons of the cerebral cortex, basal ganglia, hippocampus, cerebellum and the olfactory bulb. {epsilon}-sarcoglycan is located at the plasma membrane in neurons, muscle and transfected cells. To determine the effect of MDS-associated mutations on the function of {epsilon}-sarcoglycan we examined the biosynthesis and trafficking of wild type and mutant proteins in cultured cells. By contrast to the wild type protein, disease-associated {epsilon}-sarcoglycan missense mutations (H36P, H36R and L172R) produce proteins that are undetectable at the cell surface and are retained intracellularly. These mutant proteins become polyubiquitinated and are rapidly degraded by the proteasome. Furthermore, torsinA, that is mutated in DYT1 dystonia, a rare type of primary dystonia, binds to and promotes the degradation of {epsilon}-sarcoglycan mutants when both proteins are co-expressed. These data demonstrate that some MDS-associated mutations in SGCE impair trafficking of the mutant protein to the plasma membrane and suggest a role for torsinA and the ubiquitin proteasome system in the recognition and processing of misfolded {epsilon}-sarcoglycan.

3 Present address: Skirball Institute of Biomolecular Medicine, Developmental Genetics Program, NYU School of Medicine, 540, First Ave. New York, NY 10016.

+ These authors contributed equally to the paper.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Am. J. Pathol.Home page
S. Gastaldello, S. D'Angelo, S. Franzoso, M. Fanin, C. Angelini, R. Betto, and D. Sandona
Inhibition of Proteasome Activity Promotes the Correct Localization of Disease-Causing {alpha}-Sarcoglycan Mutants in HEK-293 Cells Constitutively Expressing {beta}-, {gamma}-, and {delta}-Sarcoglycan
Am. J. Pathol., July 1, 2008; 173(1): 170 - 181.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
F. Asmus, L. E. Hjermind, E. Dupont, J. Wagenstaller, E. Haberlandt, M. Munz, T. M. Strom, and T. Gasser
Genomic deletion size at the epsilon-sarcoglycan locus determines the clinical phenotype
Brain, October 1, 2007; 130(10): 2736 - 2745.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
P. T. Atlason, M. L. Garside, E. Meddows, P. Whiting, and R. A. J. McIlhinney
N-Methyl-D-aspartate (NMDA) Receptor Subunit NR1 Forms the Substrate for Oligomeric Assembly of the NMDA Receptor
J. Biol. Chem., August 31, 2007; 282(35): 25299 - 25307.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
J. W. Hewett, B. Tannous, B. P. Niland, F. C. Nery, J. Zeng, Y. Li, and X. O. Breakefield
Mutant torsinA interferes with protein processing through the secretory pathway in DYT1 dystonia cells
PNAS, April 24, 2007; 104(17): 7271 - 7276.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.